Determination of Regulatory Review Period for Purposes of Patent Extension; PYLARIFY

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of PYLARIFY, a human drug product, following submissions to the U.S. Patent and Trademark Office (USPTO).